TAG press release
Treatment Action Group (TAG) released a report providing a first-of-its-kind analysis of the global supply chains of QS-21 and MPL, two adjuvants used in licensed vaccines against malaria, shingles, respiratory syncytial virus, and a promising candidate vaccine for TB called M72/AS01E. The report concludes with recommendations on how supply chains for adjuvants can be strengthened through greater transparency, competition, and sustainability with the goal of maximizing the global health impact of adjuvant development for equitable access to vaccines.
Read the full press release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #39, 21 December 2025).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Treatment Action Group
Related HIV and Co-Infections News
-
U.S. Department of State: America First Global Health Strategy – bilateral agreements with Nigerian, Cameroon and Mozambique
-
The potential of new TB vaccines offers hope at the Union Conference in a year of crisis
-
[Press release] WHO releases guidance on evidence generation on new regimens for TB preventive treatment
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.